Minimally invasive tests for the accurate diagnosis of Lewy Body Dementia and Parkinson’s Disease

ESPDx is developing scalable liquid-biopsy tests based upon measurements of disease specific biomarkers in Extracellular Vesicles (EVs) purified from blood and saliva. ESPDs’s technology provides superior sensitivity and specifity, allows detection of early stages of neurological disorders such as the Lewy Body Disorders (Parkinson’s Disease and Lewy Body Dementia) and a different diagnosis of Alzheimer’s.

Earlier this year, ESPDX took part in the Innovation Observatory’s Industry Sprint which saw a group of national Health and Life Science businesses undertake various sessions with our team over the course of a week. We guided them through how to use our data and resources to aid a detailed market assessment, competitive market & gap analysis and by bringing in funding experts from the wider ecosystem they were able to utilise this evidence in their grant applications and investor pitches. 

From this ESPDX produced a competitive market analysis, a report and a finalised study achieved by horizon scanning. The competitive market analysis identified who the key companies are within the Alzheimer’s and Parkinson’s diagnostic market along with in-depth background information plus companies’ perceived strengths and weaknesses and the key ‘takeaway’s from this task. A list of potential funders was identified for ESPDx along with an extensive list of Pipeline Technologies (drugs) for Dementia with Lewy Bodies Related conditions with relevant links to research further.

 

“Providing the opportunity for SMEs to talk to one another and the experts from the IO is very valuable. This is an important role that the innovation observatory plays in helping pull people together to exchange useful knowledge and insights”

“The bit that was really useful was being directed to a source of information obtained by using horizon scanning methodologies to provide data on the therapeutics in development around dementia with lewy bodies.”

Dr. Dale Athey CEO at ESP

 

If you are a health and life sciences business, then find out more about you can utilise NIHR Innovation Observatory’s data and insights as well as conducting your own horizon scans!

Take a look at our industry page here